Results
|
1.
|
Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. MedStar authors:
Year: 2019
Citation: - Thyroid. 29(4):461-470, 2019 04.
Institution: - MedStar Washington Hospital Center
Department: - Medicine/Nuclear Medicine
Medline publication type:
All authors: - Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, Dillehay G, Draganescu C, Flux G, Fuhrer D, Giovanella L, Greenspan B, Hegedus L, Luster M, Muylle K, Smit JWA, Tuttle RM, Van Nostrand D, Verburg FA
|
|
2.
|
Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. MedStar authors:
- Burman, Kenneth D
- Klubo-Gwiezdzinska, Joanna
- Mete, Mihriye
- Van Nostrand, Douglas
- Wartofsky, Leonard
Citation: - Thyroid. 22(3):310-7, 2012 Mar.
Institution:
- MedStar Health Research Institute
- MedStar Washington Hospital Center
Department:
- Medicine/Endocrinology
- Medicine/Nuclear Medicine
Medline publication type:
- Comparative Study
- Journal Article
All authors: - Burman KD, Jonklaas J, Klubo-Gwiezdzinska J, Mete M, Van Nostrand D, Wartofsky L
|
|
3.
|
Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in 124I-PET/CT based dosimetry for 131I therapy of metastatic differentiated thyroid cancer. MedStar authors:
- Atkins, Francis
- Garcia, Carlos
- Van Nostrand, Douglas
Year: 2017
Citation: - Journal of Nuclear Medicine. 58(7):1146-1154, 2017 Jul
Institution: - MedStar Washington Hospital Center
Department: - Medicine/Nuclear Medicine
Medline publication type:
All authors: - Atkins F, Garcia C, Hobbs RF, Huang K, Plyku D, Sgouros G, Van Nostrand D
|